 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CB-AC-02 / CHA Bio & Diostech
Enrollment closed, Trial completion date, Trial primary completion date: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 7, 2024
P1/2, N=24, Active, not recruiting, Sponsor: CHABiotech CO., Ltd
Unknown status --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
- | CB-AC-02 / CHA Bio & Diostech
Enrollment open, Trial completion date, Trial primary completion date: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Sep 6, 2019
P1/2, N=24, Recruiting, Sponsor: CHABiotech CO., Ltd
Unknown status --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024 Not yet recruiting --> Recruiting | Trial completion date: Jun 2018 --> Dec 2021 | Trial primary completion date: Mar 2018 --> Dec 2021
- | CB-AC-02 / CHA Bio & Diostech
New P1/2 trial: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease (clinicaltrials.gov) - Sep 14, 2016
P1/2, N=24, Not yet recruiting, Sponsor: CHABiotech CO., Ltd